Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis

REFERENCES

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001. doi: 10.1038/nrdp.2018.1
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Pelechas E, Voulgari PV, Drosos AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020 Aug;40(8):1181–1191. doi: 10.1007/s00296-020-04616-2.
   PubMed Web of Science ®Google Scholar
• Markousis-Mavrogenis G, Bonou M, Vartela V, et al. Cardiovascular Magnetic Resonance Detects Inflammatory Cardiomyopathy in Symptomatic Patients with Inflammatory Joint Diseases and a Normal Routine Workup. J Clin Med. 2022 Mar 5;11(5):1428. 10.3390/jcm11051428
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Kalpourtzi N, Alamanos Y, et al. EMENO study group. Prevalence of rheumatoid arthritis in Greece: results from the national health examination survey EMENO. Rheumatol Int. 2023;43(7):1349–1355. doi: 10.1007/s00296-023-05316-3
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Alamanos Y, Skalkou A, et al. The changing incidence of rheumatoid arthritis over time in north-west Greece: data from a referral centre. Scand J Rheumatol. 2023;52(4):327–334. doi: 10.1080/03009742.2022.2058178
   PubMed Web of Science ®Google Scholar
• Cush JJ. Rheumatoid arthritis: early diagnosis and treatment. Med Clin North Am. 2021;105(2):355–365. doi: 10.1016/j.mcna.2020.10.006
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372. doi: 10.1001/jama.2018.13103
   PubMed Web of Science ®Google Scholar
• Küçükdeveci AA Nonpharmacological treatment in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019 Oct;33(5):101482. doi: 10.1016/j.berh.2019.101482.
   PubMed Web of Science ®Google Scholar
• Thomas K, Lazarini A, Kaltsonoudis E, et al. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Ther Adv Musculoskelet Dis. 2020 Sep 28; 12:1759720X20937132. 10.1177/1759720X20937132
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Voulgari PV, Drosos AA Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol. 2022 May;18(5):485–493. doi: 10.1080/1744666X.2022.2064275.
   PubMed Web of Science ®Google Scholar
• Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis. 2006 Feb;65(2):257–60.
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Alamanos Y, Voulgari PV, Drosos AA. Epidemiology and Risk Factors for Rheumatoid Arthritis Development. Mediterr J Rheumatol. 2023 Dec 30;34(4):404–413. doi: 10.31138/mjr.301223.eaf.
   PubMedGoogle Scholar
• Venetsanopoulou AI, Alamanos Y, Voulgari PV, Drosos AA. Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol. 2022 Sep;18(9):923–931. doi: 10.1080/1744666X.2022.2106970.
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3(Suppl 3): S2. doi: 10.1186/ar4174.
   Google Scholar
• Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–47. doi: 10.18433/j3vw2f.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Drosos AA State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2022 Apr;23(6):703–711. doi: 10.1080/14656566.2022.2049238.
   PubMed Web of Science ®Google Scholar
• Mysler E, Caubet M, Lizarraga A Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis. Open Access Rheumatol. 2021 Jun 1; 13:139–152. doi: 10.2147/OARRR.S282627.
   PubMedGoogle Scholar
• Voulgari PV, Venetsanopoulou AI, Epagelis EK, Alamanos Y, Takalou I, Drosos AA. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. Ann Rheum Dis. 2007 Feb;66(2):270–1. doi: 10.1136/ard.2006.058735.
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Voulgari PV, Alamanos Y, et al. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int. 2007 Aug;27(10):935–939. doi: 10.1007/s00296-007-0330-9.
   PubMed Web of Science ®Google Scholar
• Pagnini C, Cominelli F Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention. Int J Mol Sci. 2021 Sep 24;22(19):10273. doi: 10.3390/ijms221910273.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Felice C, Papa A, et al. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol. 2017 Mar;13(3):223–233. doi: 10.1080/1744666X.2017.1243468.
   PubMed Web of Science ®Google Scholar
• van der Houwen T, van Laar J Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers. Int J Mol Sci. 2020 Apr 27;21(9):3072. doi: 10.3390/ijms21093072.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011 Aug;50(8):1445–1452. doi: 10.1093/rheumatology/ker124.
   PubMed Web of Science ®Google Scholar
• Krieckaert C, Rispens T, Wolbink G Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012 May;24(3):306–311. doi: 10.1097/BOR.0b013e3283521c4e.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009 May;21(3):211–215. doi: 10.1097/bor.0b013e328329ed8b.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Bala M, et al; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005 Apr;52(4):1020–1030. doi: 10.1002/art.20982.
   PubMedGoogle Scholar
• Maini RN, Breedveld FC, Kalden JR, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004 Apr;50(4):1051–65. doi: 10.1002/art.20159.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26–37. doi: 10.1002/art.21519.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in. early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013 Jan;72(1):64–71. doi: 10.1136/annrheumdis-2011-201247.
   PubMed Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 Jan;73(1):86–94. doi: 10.1136/annrheumdis-2013-203843.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis: a randomised, double-blind, controlled phase 4 trial. Lancet.2013 May 4;381(9877):1541–50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18. Erratum in: Lancet. 2013 Dec 7;382(9908):1878. Erratum in: Lancet. 2013 May 4;381(9877):1540.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP,et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study. investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–81.
   PubMedGoogle Scholar
• Pelechas E, Voulgari PV, Drosos AA Golimumab for Rheumatoid Arthritis. J Clin Med. 2019 Mar 20;8(3):387. doi: 10.3390/jcm8030387.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Voulgari PV, Drosos AA. Golimumab, the newest TNF-α blocker, comes of age. Clin Exp Rheumatol. 2015 Jul;33(4):570–577.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results. of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009 Aug;60(8):2272–83. doi: 10.1002/art.24638.
   PubMed Web of Science ®Google Scholar
• Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010 Jun;69(6):1129–1135. doi: 10.1136/ard.2009.116319.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18;374(9685):210–21. doi: 10.1016/S0140-6736(09)60506-7.
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008 Nov;58(11):3319–29. doi: 10.1002/art.23964. Erratum in: Arthritis Rheum. 2009 May;60(5):1249.
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis:. the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 Jun;68(6):797–804. doi: 10.1136/ard.2008.101659.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009 Jun;68(6):805–811. doi: 10.1136/ard.2008.099291.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010 Jan;62(1):22–32. doi: 10.1002/art.27227.
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007848.
   Google Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275. doi: 10.1371/journal.pone.0030275
   PubMed Web of Science ®Google Scholar
• R F, R L, J S S. Review of head-to-head study designs in rheumatoid arthritis. Semin Arthritis Rheum. 2016 Dec;46(3):279–285. doi: 10.1016/j.semarthrit.2016.07.006.
   PubMed Web of Science ®Google Scholar
• Salomon-Escoto K, Kay J The “Treat to Target” Approach to Rheumatoid Arthritis. Rheum Dis Clin North Am. 2019 Nov;45(4):487–504. doi: 10.1016/j.rdc.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015 Aug 15;1(Suppl 1):e000057. doi: 10.1136/rmdopen-2015-000057.
   PubMedGoogle Scholar
• Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. The Lancet. 1999 May 8;353(9164):1568–1573. doi: 10.1016/s0140-6736(98)08513-4.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263–9. doi: 10.1016/S0140-6736(04)16676-2.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3–15. doi: 10.1136/annrheumdis-2015-207524.
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443–9. doi: 10.1136/ard.2007.071092.
   PubMed Web of Science ®Google Scholar
• Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012 Jun;71(6):845–850. doi: 10.1136/annrheumdis-2011-200274.
   PubMed Web of Science ®Google Scholar
• Song JJ, Song YW, Bae SC, et al. Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea. J Korean Med Sci. 2018 Dec 18;33(52):e346. doi: 10.3346/jkms.2018.33.e346.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Landewé RB, van der Heijde D, et al. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann Rheum Dis. 2020 Apr;79(4):453–459. doi: 10.1136/annrheumdis-2019-216819.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Reed GW, John A, et al. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 Mar;70(3):379–387. doi: 10.1002/acr.23294.
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Voulgari PV, Drosos AA Advances in non-biological drugs for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2024 Jan-Apr;25(1):45–53. doi: 10.1080/14656566.2023.2297798.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924–939.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18. doi: 10.1136/ard-2022-223356.
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Norton SJ, Carpenter L, et al; for ERAS and ERAN. Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. Rheumatology (Oxford). 2020 Jun 1;59(6):1272–1280. doi: 10.1093/rheumatology/kez461.
   PubMed Web of Science ®Google Scholar
• LANSBURY J. Quantitation of the activity of rheumatoid arthritis. 5. A method for summation of the systemic indices of rheumatoid activity. Am J Med Sci. 1956 Sep;232(3):300–10.
   PubMed Web of Science ®Google Scholar
• Haraoui B. Assessment and management of rheumatoid arthritis. J Rheumatol Suppl. 2009 Jun;82:2–10. doi: 10.3899/jrheum.090124. Erratum in: J Rheumatol. 2009 Aug;36(8):1851.
   PubMedGoogle Scholar
• Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012 May;64(5):640–647. doi: 10.1002/acr.21649.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573–86. doi: 10.1002/art.30129.
   PubMed Web of Science ®Google Scholar
• Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis. 2023 Jan;82(1):74–80. doi: 10.1136/ard-2022-223413.
   PubMed Web of Science ®Google Scholar
• Ometto F, Botsios C, Raffeiner B, et al. Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmun Rev. 2010 Jan;9(3):161–164. doi: 10.1016/j.autrev.2009.07.001.
   PubMed Web of Science ®Google Scholar
• Arts EE, Fransen J, Den Broeder AA, et al. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent cox regression analysis in a large cohort studyAnnals of the Rheumatic diseases. Ann Rheum Dis. 2017;76(10):1693.–1699. doi: 10.1136/annrheumdis-2016-210997
   Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108–1123. doi: 10.1002/art.41752.
   PubMed Web of Science ®Google Scholar
• Birkner B, Rech J, Stargardt T, et al. Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS One. 2020 Jan 2;15(1):e0226754. doi: 10.1371/journal.pone.0226754.
   PubMed Web of Science ®Google Scholar
• Vanier A, Mariette X, Tubach F, Fautrel B; STRASS Study Group. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in. Rheumatoid Arthritis Trial. Value Health. 2017 Apr;20(4):577–585. doi: 10.1016/j.jval.2017.01.005.
   Google Scholar
• van Esveld L, Cox JM, Kuijper TM, Bosch TM, Weel-Koenders AE. Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands. Ann Rheum Dis. 2023 Oct;82(10):1296–1306. doi: 10.1136/ard-2023-224190.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010 Jul;69(7):1286–1291. 10.1136/ard.2009.121491
   PubMed Web of Science ®Google Scholar
• Takai C, Ito S, Kobayashi D, et al. Two-year outcomes of infliximab discontinuation in patients with rheumatoid arthritis: a retrospective analysis from a single center. Intern Med. 2020;59(16):1963–1970. doi: 10.2169/internalmedicine.3934-19
   PubMed Web of Science ®Google Scholar
• Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. The Lancet. 2013 Mar 16;381(9870):918–929. doi: 10.1016/S0140-6736(12)61811-X.
   PubMed Web of Science ®Google Scholar
• Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013 Sep 25;15(5):R135. doi: 10.1186/ar4315.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015 Feb;74(2):389–395. doi: 10.1136/annrheumdis-2013-204016.
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K, Turesson C, Teleman A, et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open. 2016 Jan 14;2(1):e000133. doi: 10.1136/rmdopen-2015-000133.
   PubMedGoogle Scholar
• Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012 Nov;22(6):814–822. doi: 10.3109/s10165-011-0586-5.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016 Jan;75(1):52–8.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ. 2015 Apr 9;350:h1389. doi: 10.1136/bmj.h1389.
   PubMedGoogle Scholar
• Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial. (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis. 2016 Jan;75(1):59–67. doi: 10.1136/annrheumdis-2014-206696.
   PubMed Web of Science ®Google Scholar
• Raffeiner B, Botsios C, Ometto F, et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol. 2015 Jan;33(1):63–68.
   PubMed Web of Science ®Google Scholar
• Schlager L, Loiskandl M, Aletaha D, et al. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology (Oxford). 2020 Feb 1;59(2):324–334.10.1093/rheumatology/kez278
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al; TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006 Apr;54(4):1063–74. doi: 10.1002/art.21655.
   PubMedGoogle Scholar
• Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009 Jul;36(7):1429–41. doi: 10.3899/jrheum.081018. Epub 2009 Apr 15. Erratum in: J Rheumatol. 2010 May;37(5):1081. Erratum in: J Rheumatol. 2010 Oct;37(10):2198.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces. resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Jan;52(1):27–35.
   PubMed Web of Science ®Google Scholar
• Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010 Sep;69(9):1636–1642. doi: 10.1136/ard.2009.117341.
   PubMed Web of Science ®Google Scholar
• van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007 Jul;56(7):2129–34. doi: 10.1002/art.22718.
   PubMedGoogle Scholar
• Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008;18(5):460–464. doi: 10.3109/s10165-008-0089-1
   PubMed Web of Science ®Google Scholar
• Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014 Jan;73(1):75–85. doi: 10.1136/annrheumdis-2013-203440.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Oba K, Koike T, et al. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis. 2020 Jan;79(1):94–102. doi: 10.1136/annrheumdis-2019-216169.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Mar;54(3):711–5. doi: 10.1002/art.21671.
   PubMed Web of Science ®Google Scholar
• Berkhout LC, l’Ami MJ, Ruwaard J, et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med 2019;11:eaat3356. doi:10.1126/scitranslmed.aat3356.
   PubMed Web of Science ®Google Scholar
• Ogura T, Hirata A, Kagtagiri T, et alAB0381 ULTRASONOGRAPHY TO PREDICT FLARE AFTER DISCONTINUATION OF BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REMISSION Annals of the Rheumatic Diseases 2022;81:1317.
   Google Scholar
• van der Leeuw MS, Messelink MA, Tekstra J, Medina O, van Laar JM, Haitjema S, Lafeber F, Veris-van Dieren JJ, van der Goes MC, den Broeder AA, Welsing PMJ. Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions. Arthritis Res Ther. 2022 Mar 23;24(1):74.
   PubMed Web of Science ®Google Scholar
• Sakashita E, Nagatani K, Endo H, et al. Biomarker combination predicting imminent relapse after discontinuation of biological drugs in patients with rheumatoid arthritis in remission. PLoS One. 2024 Mar 21;19(3):e0299450. 10.1371/journal.pone.0299450
   PubMed Web of Science ®Google Scholar
• Vodencarevic A, Tascilar K, Hartmann F, et al.; RETRO study group. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther. 2021 Feb 27;23(1):67.10.1186/s13075-021-02439-5
   PubMedGoogle Scholar
• Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, et al; Dutch National POET Collaboration. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease. or Low Disease Activity: Results From a Pragmatic Open-Label Trial. Arthritis Rheumatol. 2018 Oct;70(10):1557–1564. doi: 10.1002/art.40546.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Kaltsonoudis E, et al. Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. Curr Rheumatol Rep. 2020 Jun 26;22(8):44. doi: 10.1007/s11926-020-00921-8.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol. 2020 Apr;39(4):1363–1368. doi: 10.1007/s10067-020-05001-x.
   PubMed Web of Science ®Google Scholar
• Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7(4):R784–95. doi: 10.1186/ar1733.
   PubMed Web of Science ®Google Scholar
• Emery P, Salmon M Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995 Dec;54(12):944–947. doi: 10.1136/ard.54.12.944.
   PubMed Web of Science ®Google Scholar
• Möttönen T, Hannonen P, Korpela M, et al; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002 Apr;46(4):894–8.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, Durez P, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. The Lancet. 2008 Aug 2;372(9636):375–382. doi: 10.1016/S0140-6736(08)61000-4.
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004;200:277–85.
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis. 2023 Nov;82(11):1394–1403. doi: 10.1136/ard-2023-224476.
   PubMed Web of Science ®Google Scholar
• Sidiropoulos P, Bounas A, Athanassiou P, et al. Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. Clin Rheumatol. 2020 Dec;39(12):3643–3652. doi: 10.1007/s10067-020-05171-8.
   PubMed Web of Science ®Google Scholar
• Mathijssen EGE, Vriezekolk JE, Popa CD, et al. Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations. Ann Rheum Dis. 2020 Feb;79(2):170–175.10.1136/annrheumdis-2019-216137
   PubMed Web of Science ®Google Scholar